Seclidemstat (SP-2577) is an inhibitor of LSD1/KDM1A, currently being evaluated in combination with AZA for MDS/CMML, following HMA-failure in a phase 1/2 study (NCT04734990) [44]. Here, KDM1A is linked to myelodysplastic syndrome.